secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001104659-23-056889
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma reports record Q1 revs $106.8M (+65.6% YoY), raises FY2023 guidance across all metrics
--------------------------------------------------------------------------------

- Record net revenue of $106.8M, up 65.6% YoY; GAAP net income $1.0M, diluted EPS $0.06.
- Adjusted non-GAAP EBITDA $33.0M (vs $4.3M Q1 2022); adj. diluted EPS $1.17 (vs -$0.12).
- Cortrophin Gel net sales $16.3M (Q1 2022: $1.3M); FY guidance maintained at $80-90M.
- Raised FY2023 guidance: rev $385-410M (from $360-385M), adj. EBITDA $97-107M, adj. EPS $2.99-3.45.
- Generics revenue $63.7M (+29.7% YoY); established brands/other $26.7M (+90.0%). FDA inspection with zero 483s.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000110465923056889/0001104659-23-056889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000110465923056889/tm2314831d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-056889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer